Anika Celebrates 25th Anniversary & Inaugurates Newly Expanded & Consolidated Global Manufacturing Facility in Bedford, Massa...
May 23 2017 - 8:30AM
Business Wire
Ribbon-Cutting Ceremony Opens the Doors to
State-of-the-Art Facility Built to Supply Global Demand for Anika’s
Extensive Commercial Portfolio of More than 20 Products and
Technologies
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated
orthopedics medicines company specializing in therapeutics based on
its proprietary hyaluronic acid ("HA") technology, is hosting a
celebration today at its Bedford, Massachusetts headquarters to
commemorate its 25th anniversary and inaugurate its newly-expanded
and consolidated global manufacturing facility. Previously, Anika’s
manufacturing operations were split between its U.S. headquarters
and a contract manufacturer in Abano Terme, Italy, but the company
initiated plans to onshore manufacturing in the U.S. to maintain
better control of supply chain, accelerate product development, and
increase operating efficiency. By year end, our 134,000 square foot
corporate headquarters and the newly expanded state-of-the-art
facility will manufacture and package the totality of the company’s
diverse portfolio of more than 20 products for distribution into
more than 55 markets across the globe.
“We are proud and excited to consolidate our entire
manufacturing operation in the United States on the 25th
anniversary of our inception,” said Charles H. Sherwood, Ph.D.,
President and Chief Executive Officer, Anika Therapeutics. “The new
facility not only helps Anika more deftly manage global supply and
inventory, but it also creates opportunities for a highly-skilled
workforce, and brings sophisticated scientific capabilities and
cutting-edge technologies back to the U.S. and to the state of
Massachusetts, which has been a steadfast and supportive partner
throughout our 25-year journey.”
Anika develops, manufactures and commercializes a diverse range
of therapeutic products, the large majority of which are based on
its proprietary formulation of non-animal-derived HA, a naturally
occurring substance in the human body with lubricating, healing,
restorative and regenerative properties. In the Bedford-based
manufacturing facility, Anika utilizes proprietary processes to
produce its suite of unique gel-based and textile-form products
from highly-concentrated and ultra-pure HA. Anika’s Bedford-based
manufacturing facility and corporate headquarters employs
approximately 100 operations, engineering, clinical, assembly,
warehouse, marketing, general and administrative professionals, and
it is the only facility in the U.S. with the sophisticated
capability to produce HA products in solid textile forms.
“We welcome Anika Therapeutics’ decision to bring its healthcare
manufacturing sector back to the U.S. and to the Commonwealth as
they celebrate 25 years supporting our local economy,” said
Governor Charlie Baker. “Our strong and talented workforce is
helping businesses large and small thrive, supporting economic
growth and new jobs across Massachusetts.”
“For 25 years Anika Therapeutics has provided value and
stability to not just the life sciences industry, but the
Commonwealth as a whole. With this upcoming expansion, the
anticipated and sustained impact on the local and state economy
cannot be overstated,” Travis McCready, President & CEO of the
Massachusetts Life Sciences Center said. “On behalf of the
Massachusetts Life Sciences Center, I congratulate Anika on these
first 25 years, and look forward to their continued success for the
next quarter century and beyond, here in Massachusetts.”
“Congratulations to Anika and its leadership on celebrating 25
years of success and growth,” said Robert K. Coughlin, CEO and
President of MassBio. “Their longevity and commitment to innovation
is a shining example for other Massachusetts companies who are
looking to follow their lead.”
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated
orthopedic medicines company based in Bedford, Massachusetts. Anika
is committed to improving the lives of patients with degenerative
orthopedic diseases and traumatic conditions with clinically
meaningful therapies along the continuum of care, from palliative
pain management to regenerative cartilage repair. The Company has
over two decades of global expertise developing, manufacturing, and
commercializing more than 20 products based on its proprietary
hyaluronic acid (HA) technology. Anika's orthopedic medicine
portfolio includes ORTHOVISC®, MONOVISC®, and CINGAL®, which
alleviate pain and restore joint function by replenishing depleted
HA, and HYALOFAST®, a solid HA-based scaffold to aid cartilage
repair and regeneration. For more information about Anika, please
visit www.anikatherapeutics.com.
Forward-Looking Statements
The statements made in the last sentence of the first paragraph
of this press release, which are not statements of historical fact,
are forward-looking statements within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These statements
include, but are not limited to, those relating to the Company's
expectations regarding 2017 production capabilities. These
statements are based upon the current beliefs and expectations of
the Company's management and are subject to significant risks,
uncertainties, and other factors. The Company's actual results
could differ materially from any anticipated future results,
performance, or achievements described in the forward-looking
statements as a result of a number of factors including, but not
limited to, (i) the Company's ability to successfully commence
and/or complete clinical trials of its products on a timely basis
or at all; (ii) the Company's ability to obtain pre-clinical or
clinical data to support domestic and international pre-market
approval applications, 510(k) applications, or new drug
applications, or to timely file and receive FDA or other regulatory
approvals or clearances of its products; (iii) that such approvals
will not be obtained in a timely manner or without the need for
additional clinical trials, other testing or regulatory
submissions, as applicable; (iv) the Company's research and product
development efforts and their relative success, including whether
we have any meaningful sales of any new products resulting from
such efforts; (v) the cost effectiveness and efficiency of the
Company's clinical studies, manufacturing operations, and
production planning; (vi) the strength of the economies in which
the Company operates or will be operating, as well as the political
stability of any of those geographic areas; (vii) future
determinations by the Company to allocate resources to products and
in directions not presently contemplated; (viii) the Company's
ability to successfully commercialize its products, in the U.S. and
abroad; (ix) the Company's ability to provide an adequate and
timely supply of its products to its customers; and (x) the
Company's ability to achieve its growth targets. Additional factors
and risks are described in the Company's periodic reports filed
with the Securities and Exchange Commission, and they are available
on the SEC's website at www.sec.gov. Forward-looking statements are
made based on information available to the Company on the date of
this press release, and the Company assumes no obligation to update
the information contained in this press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170523005240/en/
For Investor Inquiries:Anika Therapeutics, Inc.Sylvia Cheung,
781-457-9000Chief Financial OfficerorFor Media Inquiries:Pure
CommunicationsSusan Heins, 864-286-9597
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Sep 2023 to Sep 2024